Education
About Us
Working with TipRanks
Follow Us
Jonathan Anderman Insider Profile
4 Followers
Jonathan Anderman, Gen Counsel & Corporate Sec at Compass Therapeutics, holds 21.00K shares in Compass Therapeutics (Ticker: CMPX). Most recently, Jonathan Anderman Bought $20,000 shares of Compass Therapeutics on Apr 08, 2025 for an estimated value of 30.80K.
Jonathan Anderman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jonathan Anderman's holdings
Insider Roles
Gen Counsel & Corporate Sec
Roles that Jonathan Anderman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jonathan Anderman
Jonathan Anderman's Trading History
List of latest transactions for each holding click on a transaction to see Jonathan Anderman's performance on stock
You May Also Like
Jonathan Anderman insider profile FAQ
What is the percentage of profitable transactions made by Jonathan Anderman?
The percentage of profitable transactions made by Jonathan Anderman is ―.
What is the average return per transaction made by Jonathan Anderman?
The average return per transaction made by Jonathan Anderman is ―.
What stocks does Jonathan Anderman hold?
Jonathan Anderman holds: CMPX stocks.
What was Jonathan Anderman’s latest transaction?
Jonathan Anderman latest transaction was an Informative Buy of $30.80K.
What was Jonathan Anderman's most profitable transaction?
Jonathan Anderman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jonathan Anderman's role in Compass Therapeutics?
Jonathan Anderman's role in Compass Therapeutics is Gen Counsel & Corporate Sec.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.